TABLE 1.
Characteristics of patients and voriconazole treatment
| Characteristic | Value |
|---|---|
| No. of patients | 101 |
| Age (yr) (median [range]) | 47 (17–77) |
| Body weight (kg) (median [range]) | 54.6 (38.6–104.8) |
| Sex (n [%]) | |
| Male | 64 (63) |
| Female | 37 (37) |
| Disease type (n [%]) | |
| Acute myeloid leukemia | 44 (45) |
| Acute lymphoblastic leukemia | 19 (20) |
| Myelodysplastic syndrome | 24 (23) |
| Chronic myelomonocytic leukemia | 4 (5) |
| Non-Hodgkin's lymphoma | 9 (3) |
| Severe aplastic anemia | 1 (1) |
| Serum creatinine at baseline (mg/dl) (median [range]) | 0.60 (0.26–1.49) |
| Duration of intravenous VRC treatment (days) (median [range]) | 27 (7–99) |
| Intravenous VRC daily dose (mg/day) (median [range]) | 6.88 (2.75–10.42) |
| Cumulative dose of intravenous VRC (mg/kg) (median [range]) | 195 (40–646) |
| Indication for intravenous VRC (n [%]) | |
| Prophylaxis | 21 (21) |
| Empirical or preemptive therapy | 80 (79) |
| Concomitant medication (n [%]) | |
| Aminoglycosides | 18 (18) |
| Vancomycin | 63 (62) |
| Sulfamethoxazole-trimethoprim | 15 (15) |
| Foscarnet | 7 (7) |
| Calcineurin inhibitors | 67 (66) |